PD-1/PDL1 blockade may not only prevent or reverse type I NKT cell anergy and decrease suppressive activity of type II NKT cells on CD4+ T cells but it may also augment tumor immunity by preserving CD8+ T cells. This evidence concerns the gene CD4 and neoplasm.